AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 121
- Registration Number
- NCT01714726
- Locations
- 🇪🇸
Research Site, Valencia, Spain
Management of Metastatic Breast Cancer in Clinical Practice - Retrospective Study
Completed
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 171
- Registration Number
- NCT01715155
- Locations
- 🇧🇬
Research Site, Stara Zagora, Bulgaria
🇧🇬Reaseach Site, Varna, Bulgaria
Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) Patients
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1183
- Registration Number
- NCT01713075
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
Epidemiology and Management of Metastatic Breast Cancer
Completed
- Conditions
- Breast Cancer Nos Metastatic Recurrent
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 128
- Registration Number
- NCT01711502
- Locations
- 🇷🇴
Stefan Curescu, Timisoara, Romania
🇷🇴Doina Coste Gherasim, Baia Mare, Romania
🇷🇴Mircea Dediu, Bucharest, Romania
Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever Therapy
Completed
- Conditions
- Bronchial Asthma
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2409
- Registration Number
- NCT01711840
- Locations
- 🇯🇵
Research Site, Yamanashi, D589ll00001, Japan
A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 2
Terminated
- Conditions
- Chronic Obstructive Pulmonary DiseaseCOPD
- Interventions
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2014-01-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3
- Registration Number
- NCT01708057
Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT01708044
- Locations
- 🇺🇸
Research Site, Portland, Oregon, United States
A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1147
- Registration Number
- NCT01704495
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis
Phase 2
Terminated
- Conditions
- Nonalcoholic Steatohapatitis
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT01703260
Correlation Between Patient Perception and Findings on Clinical Examination in Chronic Obstructive Pulmonary Disease (COPD) Patients
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2013-04-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT01703416